Calidi Biotherapeutics, Inc.
For the period ended Apr 29, 2026. Filed Apr 29, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Apr 29, 2026 · Filed Apr 29, 2026
Use the contents to explore the available documents and sections.
Contents
APPENDIX B
AMENDMENT TO
CALIDI BIOTHERAPEUTICS, INC.
2023 EQUITY INCENTIVE PLAN
Section 2.1 of the Plan is hereby amended and restated in its entirety as follows:
“2.1. Number of Shares Available. Subject to Sections 2.6 and 21 and the other applicable provisions of this Plan, the total number of Shares reserved and available for grant and issuance under this Plan shall be 1,950,000 Shares, or such lesser number of Shares as determined by the Board at such time.”
Capitalized terms used but not defined in this amendment have the meanings given to them in the Company’s 2023 Equity Incentive Plan.
B-1
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.